1
|
Pizzi M, Lorenzi L, Scarmozzino F, Albertini E, Balzarini P, Sbaraglia M, Santoro L, Chiudinelli M, Mussolin L, Carraro E, Cutrone C, Casola S, Pellegrini V, Nalio S, Bonaldi L, Pillon M, Dei Tos AP. Reactive Bcl2-positive germinal centres in paediatric tonsils: expanding the spectrum of lymphoma mimickers in children and adolescents. Histopathology 2025. [PMID: 40289261 DOI: 10.1111/his.15460] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/20/2024] [Revised: 02/27/2025] [Accepted: 04/06/2025] [Indexed: 04/30/2025]
Abstract
AIMS Bcl2-positive germinal centres (GCs) have never been documented in reactive lymphoid hyperplasia (RLH). Here we describe such phenomenon in paediatric chronic tonsillitis (PCT), addressing the differential diagnosis with paediatric lymphomas. METHODS AND RESULTS Six PCT cases with Bcl2-positive GCs were retrieved from a retrospective series of 166 tonsillectomies from children and adolescents. Clinical-pathological data were collected, also considering the status of IG rearrangements and BCL2 translocations. PCT with Bcl2-positive GCs mostly occurred in males (5/6 cases; median age: 5 years). Histologically, tonsil architecture was preserved and Bcl2 positivity was documented in a minority of GCs. Bcl2-positive GCs expressed CD10 and Bcl6 and had a high proliferation index. All cases had polyclonal IG rearrangements without evidence of monotypic kappa and lambda chains by RNAscope. BCL2 translocations were lacking in all the cases. CONCLUSION Bcl2-positive GCs in PCT are a rare and benign phenomenon, expanding the spectrum of lymphoma-mimicking paediatric RLH.
Collapse
Affiliation(s)
- Marco Pizzi
- Pathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy
| | - Luisa Lorenzi
- Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Federico Scarmozzino
- Pathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy
| | - Emma Albertini
- Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Piera Balzarini
- Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Marta Sbaraglia
- Pathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy
| | - Luisa Santoro
- Pathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy
| | | | - Lara Mussolin
- Oncohematology Unit, Department of Woman and Child Health, University of Padua School of Medicine, Padua, Italy
| | - Elisa Carraro
- Oncohematology Unit, Department of Woman and Child Health, University of Padua School of Medicine, Padua, Italy
| | - Cesare Cutrone
- Otolaryngology Unit, Department of Neurosciences, University of Padua School of Medicine, Padua, Italy
| | - Stefano Casola
- Genetics of B cells and Lymphoma unit, IFOM ETS-The AIRC Institute of Molecular Oncology, Milan, Italy
- Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
| | - Vilma Pellegrini
- Pathology Unit, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy
| | - Silvia Nalio
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Laura Bonaldi
- Immunology and Molecular Oncology Diagnostics, Veneto Institute of Oncology, IOV-IRCCS, Padua, Italy
| | - Marta Pillon
- Oncohematology Unit, Department of Woman and Child Health, University of Padua School of Medicine, Padua, Italy
| | - Angelo Paolo Dei Tos
- Pathology Unit, Department of Medicine-DIMED, University of Padua School of Medicine, Padua, Italy
| |
Collapse
|
2
|
Altube A, Marsol N, Rey Deutsch AC, Malusardi C, Sciaccaluga D, Cabral C, Auat M. Detection of normal B cell precursors in lymph nodes samples. Int J Lab Hematol 2023; 45:592-595. [PMID: 36797825 DOI: 10.1111/ijlh.14037] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/03/2022] [Accepted: 01/24/2023] [Indexed: 02/18/2023]
Affiliation(s)
- Alejandra Altube
- Flow Cytometry Laboratory, Hematology Division, Hospital de Clínicas "José de San Martín", University of Buenos Aires, Buenos Aires, Argentina
| | - Nicolás Marsol
- Hematology Division, Hospital de Clínicas "José de San Martín", University of Buenos Aires, Buenos Aires, Argentina
| | - Ana Clara Rey Deutsch
- Hematology Division, Hospital de Clínicas "José de San Martín", University of Buenos Aires, Buenos Aires, Argentina
| | - Cecilia Malusardi
- Flow Cytometry Laboratory, Hematology Division, Hospital de Clínicas "José de San Martín", University of Buenos Aires, Buenos Aires, Argentina
| | - Dolores Sciaccaluga
- Pathology Department, Hospital de Clínicas "José de San Martín", University of Buenos Aires, Buenos Aires, Argentina
| | - Cecilia Cabral
- Pathology Department, Hospital de Clínicas "José de San Martín", University of Buenos Aires, Buenos Aires, Argentina
| | - Mariangeles Auat
- Flow Cytometry Laboratory, Hematology Division, Hospital de Clínicas "José de San Martín", University of Buenos Aires, Buenos Aires, Argentina
| |
Collapse
|
3
|
Saglam A, Singh K, Gollapudi S, Kumar J, Brar N, Butzmann A, Warnke R, Ohgami RS. Indolent T-lymphoblastic proliferation: A systematic review of the literature analyzing the epidemiologic, clinical, and pathologic features of 45 cases. Int J Lab Hematol 2022; 44:700-711. [PMID: 35577551 DOI: 10.1111/ijlh.13873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Accepted: 04/25/2022] [Indexed: 11/26/2022]
Abstract
An indolent T-lymphoblastic proliferation (iT-LBP) is a rare benign disorder characterized by an abnormal expansion of immature T-cells, which morphologically can mimic malignancy. Since the first case was described in 1999, dozens more have been reported in the literature. However, the epidemiologic, clinical, pathologic, and biologic features of this disease have not been well described. Here, we retrospectively reviewed all known cases reported in the literature to better understand this entity. A PubMed search up to January 2022 highlighted 25 papers describing cases/case series of iT-LBP, one of which was a case presentation in a slide workshop. Except for 9 of the cases in one of the papers, where it was evident that the number of CD3+/TdT+ cells were too few to conform with a diagnosis of iT-LBP, all papers and all the cases reported were included in the study amounting to a total of 45 cases. Clinicopathologic characteristics were analyzed using descriptive statistics and frequencies. Our analysis highlighted the previously known association with Castleman disease and Castleman-like features and underlined its association with dendritic cell proliferations in general, as well as uncovering high frequency of concurrence with hepatocellular carcinoma and autoimmune diseases, most notably myasthenia gravis, paraneoplastic pemphigus and paraneoplastic autoimmune multiorgan syndrome. Furthermore, the co-expression of CD4 and CD8 and high prevalence of extranodal disease and recurrences were other less well described features that were revealed.
Collapse
Affiliation(s)
- Arzu Saglam
- Department of Pathology, Hacettepe University, Ankara, Turkey
| | - Kunwar Singh
- Department of Pathology, University of California San Francisco, San Francisco, California, USA
| | - Sumanth Gollapudi
- Department of Pathology, University of California San Francisco, San Francisco, California, USA
| | - Jyoti Kumar
- Department of Pathology, Stanford University, Stanford, California, USA
| | - Nivaz Brar
- Department of Pathology, Stanford University, Stanford, California, USA
| | - Alexandra Butzmann
- Department of Pathology, University of California San Francisco, San Francisco, California, USA
| | - Roger Warnke
- Department of Pathology, Stanford University, Stanford, California, USA
| | - Robert S Ohgami
- Department of Pathology, University of California San Francisco, San Francisco, California, USA
| |
Collapse
|
4
|
Stone AB, Grzywacz BJ, Courville EL, Linden MA. Indolent B-Lineage Precursor Populations Identified by Flow Cytometry and Immunohistochemistry in Benign Lymph Nodes. Am J Clin Pathol 2022; 157:202-211. [PMID: 34528663 DOI: 10.1093/ajcp/aqab120] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 06/14/2021] [Indexed: 11/14/2022] Open
Abstract
OBJECTIVES In this retrospective study, we report a series of benign lymph nodes showing small populations of normal B-cell precursors characterized by flow cytometry and immunohistochemistry. METHODS Ten cases identified during clinical flow cytometry practice were retrospectively reanalyzed with particular attention to hematogone categorization and enumeration. Immunohistochemical staining was performed on five excisional lymph node biopsy specimens to characterize the morphologic correlate. RESULTS Populations of hematogones ranging from 0.13% to 1.86% (median, 0.51%) of all viable leukocytes were demonstrated in 10 benign lymph node samples from eight different patients ranging in age from 17 to 45 years (median, 37.5). These hematogones showed a characteristic immunophenotype (CD19+/CD10+) and maturational pattern by flow cytometry, with progression from stage 1 (median, 0.03%) to stage 2 (median, 0.19%) to stage 3 (median, 0.26%) seen in all cases. Immunohistochemical staining on five excisional biopsy specimens demonstrated a distinct perisinusoidal distribution of CD10+/CD20+ cells with a subset of TdT+ cells, providing a morphologic correlate. CONCLUSIONS To our knowledge, this is the first study to characterize distinct hematogone populations within benign lymph nodes by both flow cytometry and immunohistochemistry. Recognizing these normal B-cell precursor populations is important to avoid their miscategorization as a CD10+ B-cell neoplasm.
Collapse
Affiliation(s)
- Andrew B Stone
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA
| | - Bartosz J Grzywacz
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA
| | | | - Michael A Linden
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA
| |
Collapse
|
5
|
Bhavsar S, Liu YC, Gibson SE, Moore EM, Swerdlow SH. Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity. Am J Surg Pathol 2021; 46:71-82. [PMID: 34392269 DOI: 10.1097/pas.0000000000001750] [Citation(s) in RCA: 29] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
In the current World Health Organization classification, terminal deoxynucleotidyl transferase (TdT) expression in a high grade/large cell B-cell lymphoma (LBCL) indicates a B-lymphoblastic lymphoma/leukemia (B-LBL), although TdT expression in what appear to be mature LBCL or following mature B-cell neoplasms is reported. The frequency of TdT+ LBCL, how to best categorize these cases, and their clinicopathologic features, molecular landscape, and relationship to classic B-LBL remain to be better defined. TdT expression was therefore assessed in 258 LBCL and the results correlated with the cytologic, phenotypic, and cytogenetic findings. Targeted mutational analysis, review of prior biopsies, and assessment of clinical associations was performed in the 6 cases with >10% TdT+ cells. All 6 TdT+ LBCL were blastoid-appearing, CD34-, MYC+, BCL2+, and had MYC rearrangements (R) (5/6 with BCL2 and/or BCL6-R). 5/6 had a prior TdT- LBCL and/or follicular lymphoma and all had an aggressive course. Fifteen nonsynonymous variants in 11 genes were seen in the 4/5 tested cases with mutations. TdT+ and TdT- areas in 1 case showed identical mutations. The mutational profiles were more like those reported in germinal center B-cell type-diffuse LBCL rather than B-LBL. Evolution from preceding TdT- lymphomas was nondivergent in 1/3 tested cases and partially divergent in 2. The clinicopathologic and cytogenetic features of these 6 cases were similar to those found in a meta-analysis that included additional cases of TdT+ LBCL or B-LBL following follicular lymphoma. Thus, TdT+, CD34- large B-cell neoplasms with MYC rearrangements and often a "double hit" are rare, frequently a transformational event and aggressive but are distinct from classic B-LBL.
Collapse
Affiliation(s)
- Shweta Bhavsar
- Department of Pathology, UPMC Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA
| | | | | | | | | |
Collapse
|
6
|
Mantle cell lymphomas with concomitant MYC and CCND1 breakpoints are recurrently TdT positive and frequently show high-grade pathological and genetic features. Virchows Arch 2021; 479:133-145. [PMID: 33528622 DOI: 10.1007/s00428-021-03022-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2020] [Revised: 12/28/2020] [Accepted: 01/06/2021] [Indexed: 12/22/2022]
Abstract
Chromosomal breakpoints involving the MYC gene locus, frequently referred to as MYC rearrangements (MYC - R+), are a diagnostic hallmark of Burkitt lymphoma and recurrent in many other subtypes of B-cell lymphomas including follicular lymphoma, diffuse large B-cell lymphoma and other high-grade B-cell lymphomas and are associated with an aggressive clinical course. In remarkable contrast, in MCL, only few MYC - R+ cases have yet been described. In the current study, we have retrospectively analysed 16 samples (MYC - R+, n = 15, MYC - R-, n = 1) from 13 patients and describe their morphological, immunophenotypic and (molecular) genetic features and clonal evolution patterns. Thirteen out of fifteen MYC - R+ samples showed a non-classical cytology including pleomorphic (centroblastic, immunoblastic), anaplastic or blastoid. MYC translocation partners were IG-loci in 4/11 and non-IG loci in 7/11 analysed cases. The involved IG-loci included IGH in 3 cases and IGL in one case. PAX5 was the non-IG partner in 2/7 patients. The MYC - R+ MCL reported herein frequently displayed characteristics associated with an aggressive clinical course including high genomic-complexity (6/7 samples), frequent deletions involving the CDKN2A locus (7/10 samples), high Ki-67 proliferation index (12/13 samples) and frequent P53 expression (13/13 samples). Of note, in 4/14 samples, SOX11 was not or only focally expressed and 3/13 samples showed focal or diffuse TdT-positivity presenting a diagnostic challenge as these features could point to a differential diagnosis of diffuse large B-cell lymphoma and/or lymphoblastic lymphoma/leukaemia.
Collapse
|